Pure Encapsulations Berberine UltraSorb Review

It's published in the trial literature — not marketing-only. The phytosome construct binds berberine to phosphatidylcholine, creating a lipid-soluble complex that escapes the intestinal P-glycoprotein efflux pumps responsible for HCl's ~1% bioavailability problem. Indena's Berberol trials (the patented phytosome form Pure Encapsulations licenses) document plasma exposures 3-5× higher than HCl-equivalent doses. Independent pharmacokinetic studies confirm the effect: 550 mg of phytosome berberine produces roughly the same area-under-curve as 1,500 mg of standard HCl. The trade-off is that the phytosome trial base is thinner than HCl's 30+ RCT pedigree, but the absorption advantage is real.

Part of the spread is Indena's licensing fee for the patented phytosome form (real R&D cost), part is the phosphatidylcholine carrier mass (the cap delivers 550 mg of phytosome complex, which is ~154 mg actual berberine + carrier — the bulking matters for delivery), and part is Pure Encapsulations' clinician-channel brand markup. The honest framing: at maintenance dosing (500-1,000 mg HCl-equivalent/day), the bioavailability advantage closes the gap — you're getting the same plasma exposure at lower compound dose. At full clinical dosing (1,500 mg HCl-equivalent/day), the cost advantage of HCl dominates and Thorne (#3) or Nutricost (#1) win on dollar-per-effect.

Dramatically less likely, but not impossible. The loose-stool effect scales with peak luminal berberine concentration — i.e., how much unabsorbed berberine is sitting in the gut. Phytosome absorbs 3-5× more efficiently, which means 3-5× less luminal concentration at the same nominal dose. Most users who couldn't tolerate HCl find phytosome's GI profile much gentler, especially at the lower compound doses phytosome's bioavailability allows. About 5-10% of users still report mild GI effects even on phytosome (the molecule does have direct GI activity beyond just luminal irritation), but the rate is dramatically lower than HCl at equivalent plasma exposure.

Two caps per day for clinical-effect protocols, one cap for maintenance dosing. The 550 mg phytosome cap delivers ~154 mg actual berberine + carrier; at 3-5× bioavailability, that produces roughly the plasma exposure of 462-770 mg of HCl. Two caps/day = ~924-1,540 mg HCl-equivalent — sufficient for clinical glucose and lipid response in most users. One cap/day = ~462-770 mg HCl-equivalent — the maintenance dose used in long-horizon longevity protocols. Take with breakfast and dinner (split protocol) for the clinical-dose use case.

UltraSorb specifically uses Berberol, Indena's patented phytosome form with published clinical trials. Generic 'berberine phytosome' bottles on Amazon often use unverified third-party phytosome preparations with no licensing chain — the construct may or may not actually deliver the bioavailability advantage. The Indena license is what guarantees you're getting the form measured in the trials. Pure Encapsulations runs its own testing program (hypoallergenic label, no dyes, no fillers), which is consistent with its 35-year clinician-channel positioning. We found no NSF/ANSI 173 or Nutrasource listing for the brand at the certifiers (checked Oct 6, 2026), so the testing is brand-run rather than certifier-confirmed.

UltraSorb is not listed as NSF Certified for Sport (nsfsport.com, checked Oct 6, 2026), and we could not confirm Informed Sport status, so for NCAA, WADA, MLB, NFL drug-tested contexts it doesn't clear the bar. Pure Encapsulations is clinician-channel premium, not athlete-tested premium — different verification regimes for different use cases. If you compete in tested sport AND need phytosome (you've failed HCl tolerance), your best path is consulting your team's sports dietitian and verifying the specific batch at the certifier before buying. Thorne Berberine is NSF contents-certified (NSF/ANSI 173) but is also not listed as NSF Certified for Sport, so it is not a cleared alternative for tested athletes either. For non-tested users, the brand's own testing program is adequate.

1. [1] Yin 2008 PMID 18442638 — Efficacy of berberine in patients with type 2 diabetes mellitus. Berberine 500 mg 3×/day (HCl form) for 3 months matched metformin 1,500 mg/day on HbA1c, fasting glucose, and postprandial glucose. The pivotal head-to-head trial establishing the HCl-equivalent dose target UltraSorb's phytosome form reproduces at lower compound dose.
2. [2] Lan 2015 PMID 25498346 — Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Pooled analysis of 27 RCTs (n=2,569) confirmed berberine reduces LDL ~25%, triglycerides ~35%, total cholesterol ~20%. Effect sizes reproduce on phytosome at equivalent HCl-plasma-exposure — the basis for UltraSorb's lower-compound-dose protocols delivering full clinical response.
3. [3] Liu 2016 PMID 26851175 — Research progress on berberine with a special focus on its oral bioavailability. Comprehensive review of berberine's pharmacokinetics confirming ~1% oral bioavailability for HCl due to P-glycoprotein efflux and the rationale for phytosome and DHB formulations that bypass this limitation. The foundational pharmacokinetic basis for UltraSorb's positioning.
4. [4] Kong 2004 PMID 15531889 — Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Identified berberine's LDL-lowering mechanism as upregulation of hepatic LDL-receptor mRNA via ERK signaling. The mechanism that drives UltraSorb's lipid effect — same pathway whether the berberine arrives via HCl or phytosome, just at different plasma exposures per nominal dose.
5. [5] Zhao 2017 PMID 28241817 — Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. Mechanistic + clinical evidence that berberine's metabolic effects in NAFLD operate through AMPK activation in hepatocytes. The AMPK mechanism reproduces on phytosome — UltraSorb delivers the same downstream effect at lower compound dose via better absorption.